Current topics in behavioral neurosciences最新文献

Children with extreme behavioral inhibition (BI) are at a significantly greater risk to develop anxiety disorders later in life. We and others have identified similar early-life temperamental BI in nonhuman primates (NHPs), including rhesus monkeys. NHP models of BI provide a unique opportunity to study the neurobiology of BI in a species that shares biological, developmental, and socioemotional similarities with humans. Rhesus monkey models have identified a distributed brain circuit that includes the central extended amygdala (EAc) as being critical for the genesis of BI. By leveraging multimodal neuroimaging, brain lesions, RNA-sequencing, and viral vector manipulations in rhesus monkeys, these studies have identified specific brain regions, genetic factors, and molecular mechanisms that causally contribute to BI. Here, we discuss these findings from NHPs and how they fit into a translational framework that can contribute to our understanding of the neural circuits that give rise to the risk to develop anxiety and depressive disorders.

The range of phenomena that can be induced by psychedelic substances is broad and variable, including effects on perception, cognition, and emotion. The umbrella term "psychedelic phenomenology" is used to refer to a combination of altered experiential features, such as hallucinations or ego dissolution, which together constitute a psychedelic experience. However, there is no consensus on the set of alterations of consciousness that qualifies an altered state to be a "psychedelic state." In this chapter we summarize the most commonly discussed changes in subjective experiences which could be seen as "core features" of psychedelic experiences. While acknowledging the rich history of pioneering phenomenological work of the last century, this chapter focuses on more recent developments in the quantitative work on the assessment of these phenomena. We also address the under-researched phenomenology of distressing effects, often referred to as "challenging experiences" or "bad trips," and point to their importance in understanding the therapeutic potential and risks associated with psychedelic phenomenology. Historically, one can find many links between psychedelic phenomenology and the phenomenology of psychopathology. We stress the importance to refine the assessment and description also of distressing effects, to identify factors that promote acute experiences which are beneficial and limit those which can have potentially harmful long-term effects.

Despite using the recommended anti-emetic treatments, control of nausea and vomiting is still an unmet need for cancer patients undergoing chemotherapy treatment. Few properly controlled clinical trials have evaluated the potential of exogenously administered cannabinoids or manipulations of the endogenous cannabinoid (eCB) system to treat nausea and vomiting. In this chapter, we explore the pre-clinical and human clinical trial evidence for the potential of exogenous cannabinoids and manipulations of the eCB system to reduce nausea and vomiting. Although there are limited high-quality human clinical trials, pre-clinical evidence suggests that cannabinoids and manipulations of the eCB system have anti-nausea/anti-emetic potential. The pre-clinical anti-nausea/anti-emetic evidence highlights the need for further evaluation of cannabinoids and manipulations of eCBs and other fatty acid amides in clinical trials.

Cannabis-based medicine (CBM) is used in a wide variety of different neurological disorders. While the use of CBM in the treatment of pain, AIDS wasting, loss of appetite, and spasticity is well established, CBM application in movement disorders and neurodegenerative disorders is still an emerging topic. The purpose of this chapter is to summarize current evidence behind the use of CBM in selected neurological diseases, mainly movement and neurodegenerative disorders. The best evidence for efficacy of CBM is for Tourette syndrome resulting in an improvement of tics and psychiatric comorbidities. In this indication, delta-9-tetrahydrocannabinol (THC)-containing CBMs are recommended. There is limited evidence that CBMs are also effective in Parkinson's disease in which they may improve tremor, but also non-motor symptoms such as pain and sleeping problems. With respect to other neurodegenerative diseases, there is limited evidence that CBMs may improve behavioral symptoms in Huntington's disease. In addition, it has been speculated that CBMs may have neuroprotective effects, but this has not yet been confirmed in the clinical setting.

Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymethamphetamine (MDMA), emerged during the twentieth century and have likewise seen use in a broad range of settings. Interest has arisen in the use of classical psychedelics and entactogens, together termed "psychedelics," for therapeutic purposes in Western clinical settings. Care in these settings is governed by standards for the communication and assumption of risk in the process of informed consent. Rigorous informed consent standards in psychedelic medicine are not only essential for quality care but also critical to the mitigation of risk, particularly in research settings and for vulnerable individuals. This chapter describes practical elements of informed consent in psychedelic therapy, with a focus on effective communication of the risks and potential benefits of classical psychedelic and entactogen treatments as they are currently understood.

The drive to seek information through exploratory behavior is widespread in both humans and other animals. This can be adaptive in reducing uncertainty about the best course of action within novel or changing environments. However, exploratory behaviors can also become maladaptive if subjective uncertainty levels remain too high or too low, as may happen in states of elevated anxiety. In this article, we review recent studies investigating the influence of anxiety on information-seeking behavior. We focus primarily on studies using cognitive computational models and associated behavioral tasks designed to test specific exploratory strategies, which could each be affected by anxiety in distinct ways. Results of current studies remain mixed and highlight the importance of distinguishing potential effects of task, state vs. trait anxiety, somatic vs. cognitive anxiety, and clinical vs. sub-clinical anxiety. There are also a range of different information-seeking strategies that are necessary to consider. At present, many findings could be taken to support a picture in which cognitive anxiety, and/or trait anxiety more broadly, may increase information-seeking, while somatic and/or state anxiety could have opposing effects. However, a number of previous results also appear inconsistent or task-dependent. Future studies are needed to resolve these apparent inconsistencies and more directly disentangle effects of different dimensions of anxiety on the adaptive and maladaptive use of information-seeking.

During the past 30 years, the endocannabinoid system (ECS) has emerged as a major signalling system in the mammalian brain regulating neurotransmission in numerous brain regions and in various cell populations. Endocannabinoids are able to regulate specific physiological functions and thus modify their behavioural manifestations and allostatic alterations of the ECS linked to different pathological conditions. As discussed in detail in other chapters of this book, endocannabinoids are involved in learning and memory, stress, and anxiety, feeding, energy balance, development, and ageing. Likewise, many CNS disorders (e.g. schizophrenia, epilepsy, substance use disorders, and multiple sclerosis) are associated with dysregulation of the ECS. Discerning the physiological functions of the synthetic and degrading enzymes of endocannabinoids and their receptors is a challenging task because of their distinct and complex expression patterns. Techniques of genetic engineering have been able to shed light on a number of complex ECS-related tasks during the past years. In this chapter, first, we take a critical look at the toolbox available to researchers who would like to investigate cannabinoid effects using genetic engineering techniques, then we comprehensively discuss genetically modified rodent models in various neuronal and non-neuronal cell populations, both within and outside the nervous system.

In people with schizophrenia, anxiety is highly prevalent and related to numerous negative outcomes; unfortunately, anxiety is both underreported and understudied in schizophrenia. The current review highlights the importance and utility of assessing anxiety in schizophrenia by addressing four main questions: (1) What does anxiety look like throughout the development of schizophrenia?; (2) How do we measure anxiety in schizophrenia?; (3) What are the mechanisms underlying anxiety in schizophrenia; (4) How do we treat anxiety in schizophrenia? We also provide take-home points and propose future directions for the field. We hope this emphasis on the critical role of anxiety in schizophrenia will help researchers appropriately identify the presence of anxiety, better address these symptoms, and improve the lives of people at risk for or experiencing psychosis.

With the advent of human neuroimaging, researchers were drawn to the idea that by better understanding the human brain, more effective mental health interventions could be developed. It has been more than 20 years since the first functional magnetic resonance imaging (fMRI) studies were conducted to examine changes in brain activation with anxiety-related treatments and more than 60 studies have since been published in this vein. For the current review, we conduct a systematic review of this literature, focusing on adult studies using task-based fMRI to measure brain activation changes with pharmacologic or psychotherapy interventions for phobia, social anxiety disorder, panic disorder, generalized anxiety disorder, posttraumatic stress disorder, and obsessive-compulsive disorder. Neuroscientific theories of anxiety-related disorders and their treatment have focused on prefrontal-insula-amygdala networks. Treatment-related decreases in amygdala and/or anterior insula activation were identified as the most consistent finding across disorders, with the most consistent results reported for specific phobia. Directionality of change and specific regions implicated in the prefrontal cortex were inconsistent across studies. The potential importance for probing other networks and processes as mechanisms of anxiety treatment was recognized, such as striatal regions underlying inhibitory learning or reward responsivity. Future treatment-fMRI research related to anxiety disorders would benefit from larger sample sizes, use of more nuanced computational approaches, and increased focus on replication. There is continued promise that fMRI research will enhance our understanding of how treatments work and inform the evolution of more effective or personalized mental health treatment.

In this article, we briefly overview how the expression, measurement, and treatment of anxiety in autism may be different from the general population. We review the literature on links between sensory processing differences and anxiety, which show transdiagnostic patterns but are an especially prominent feature of anxiety in autism. Specifically, we focus on how the sense of interoception, i.e., how we perceive sensory information from within our bodies, contributes to anxiety in autism. We present new findings integrating multimodal interoceptive measures and total anxiety symptoms in a sample of n = 38 non-autistic and n = 43 autistic individuals, ages 8-55 years. Using principal components analysis, we found two components relating to interoceptive confusion (i.e., self-reported ability to localize and interpret interoceptive cues): one component that closely relates to anxiety symptoms and one component that is distinct from anxiety. Interoceptive perception (i.e., performance on a lab-based task) was uniformly related to interoceptive confusion when distinguished from anxiety but showed complex relations with total anxiety symptoms. Combined, these findings suggest meaningful subtypes of interoceptive difficulties and their interrelationship with anxiety. We present conclusions and future directions for consideration of individual differences, toward creating a personalized understanding of anxiety-interoception links.